Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement
Pharmafile
APRIL 25, 2024
Prism BioLab has announced that it has entered into a target-exclusive research and licensing agreement with Ono Pharmaceutical. Under the terms of this agreement, the two companies will collaboratively develop a candidate for Ono’s oncology target using Prism’s PepMetrics technology.
Let's personalize your content